A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)

Trial Profile

A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs AAV-REP1 (Primary)
  • Indications Choroideraemia
  • Focus Registrational; Therapeutic Use
  • Acronyms STAR
  • Sponsors Nightstar Therapeutics; NightstaRx
  • Most Recent Events

    • 06 Jun 2018 According to a Nightstar Therapeutics media release, one year follow-up data from this trial is expected in 2020.
    • 03 Apr 2018 According to a Nightstar Therapeutics media release, the company anticipates that the STAR trial will be fully enrolled by the first half of 2019.
    • 05 Mar 2018 According to a NightstaRx media release, the company today announced the initiation of this STAR trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top